[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356547-105":59,"doc-detail-356547-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","treatment-response-and-outcomes-of-prostate-cancer-patients-carrying-the-germline-mms22l-f722fs-mutation","Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation","","Background: MMS22L is involved in homology-directed DNA repair, and experimental data link its loss to sensitivity to PARP inhibitors. A rare Ashkenazi Jewish founder germline loss-of-function variant, MMS22L F722fs (c.2164_2168del), has been described as a prostate cancer risk factor, but its effect on disease course after diagnosis is unclear. Methods: Longitudinal outcomes were assessed in seven carriers across prostate cancer stages identified at Johns Hopkins. Results and Conclusions: Radical prostatectomy patients showed durable, often disease-free survival without PARPi exposure, suggesting possible exceptional outcomes and good responses to standard systemic therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treatment-response-and-outcomes-of-prostate-cancer-patients-carrying-the-germline-mms22l-f722fs-mutation/356547/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treatment-response-and-outcomes-of-prostate-cancer-patients-carrying-the-germline-mms22l-f722fs-mutation/356547.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is MMS22L F722fs and why is it clinically relevant in prostate cancer?","Question",{"text":112,"@type":113},"MMS22L participates in homology-directed DNA repair, and its founder loss-of-function variant (F722fs) has been associated with increased prostate cancer risk in Ashkenazi Jewish ancestry. Preclinical models suggest MMS22L loss can confer sensitivity to PARP inhibitors, making prognosis and treatment impact important.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the patients and outcomes evaluated in this study?",{"text":117,"@type":113},"Seven MMS22L F722fs carriers with prostate cancer diagnosed at Johns Hopkins were followed longitudinally. Outcomes included survival status, disease-free status after treatment, biochemical recurrence and progression, and treatment responses reported in the series.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment response and survival outcomes were observed, and was PARPi used?",{"text":121,"@type":113},"With follow-up ranging from 5 to 27 years, five of seven patients initially treated with radical prostatectomy remained alive and disease-free, including some who received adjuvant or salvage therapies. The remaining two metastatic-at-diagnosis patients showed prolonged response to ADT in one case, while the other died of unknown causes 5 years after diagnosis; none received PARPi.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356547,1792162047,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Prostate   \nRAPID COMMUNICATION   \nTreatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation  \nMayuko Kanayama1 | Violet A. Daniels1 | Marta Gielzak1 | Alex Brame1 | Misop Han1 | Li Jia2 | Jianfeng Xu3,4  | Tamara L. Lotan1 | Mario A. Eisenberger5 | Catherine H. Marshall5  | Patrick C. Walsh1 | William B. Isaacs1 | Jun Luo1  \n1Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA | 2Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA | 3Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA | 4University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA | 5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA  \nCorrespondence: Jun Luo ([jluo2@jhmi.edu](jluo2@jhmi.edu))  \nReceived: 16 December 2025 | Revised: 9 January 2026 | Accepted: 16 January 2026  \nFunding: National Institutes of Health, Grant/Award Number: R01CA238284  \nKeywords: ancestry‐specific germline mutations | Ashkenazi Jewish ancestry | genetics | MMS22L  \nABSTRACT  \nBackground: Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi) . A rare germline loss‐of‐function founder mutation in MMS22L, F722fs (c.2164_2168del), was recently identified as a prostate cancer risk factor among individuals of Ashkenazi Jewish ancestry. The impact of this mutation on the disease course following prostate cancer diagnosis remains unclear. Here, we report the longitudinal outcomes of seven MMS22L F722fs carriers diagnosed with different stages of prostate cancer identified at the Brady Urological Institute at Johns Hopkins University.  \nMethods: We investigated the longitudinal outcomes of seven MMS22L F722fs carriers diagnosed with different stages of prostate cancer identified at the Brady Urological Institute.  \nResults: With a follow‐up time ranging from 5 to 27 years, five of the seven patients who were initially treated with radical prostatectomy remain alive and disease‐free, including two patients who had adjuvant and salvage therapies, and one patient who was cured after developing metastatic disease post‐surgery. For the remaining two patients with metastatic prostate cancer at diagnosis, one patient responded to ADT for 11 years, and the other died of unknown causes 5 years after diagnosis. None of these patients received PARPi.  \nConclusions: Although limited by its retrospective design and small cohort size, this series suggests the potential for exceptional outcomes in F722fs mutation carriers diagnosed with prostate cancer, despite the aggressive disease features and lack of treatment with PARPi. The findings also suggest that prostate cancer patients with this mutation may respond well to standard systemic treatments.  \n1 | Introduction  \nRare pathogenic germline mutations contribute to the development of hereditary prostate cancer (PCa) [1]. To identify individuals with cancer predisposition and potentially improve their care and  \noutcomes, the National Comprehensive Cancer Network (NCCN) publishes guidelines for PCa germline genetic testing [2]. NCCN‐ recommended genes include homologous recombination repair (HRR) genes (e.g., BRCA1/2, ATM, CHEK2, PALB2), DNA  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2026 The Author(s) . The Prostate published by Wiley Periodicals LLC.  \nThe Prostate, 2026; 86:727–731 727  \n[https://doi.org/10.1002/pros.70133](https://doi.org/10.1002/pro","cbCaiarbFMqN3mQk","https://ap.wps.com/l/cbCaiarbFMqN3mQk","pdf",1946030,"English","# ABSTRACT\n## Background\n## Methods\n## Results\n## Conclusions\n# 1 | Introduction\n# 2 | Methods","[{\"question\":\"What is MMS22L F722fs and why is it clinically relevant in prostate cancer?\",\"answer\":\"MMS22L participates in homology-directed DNA repair, and its founder loss-of-function variant (F722fs) has been associated with increased prostate cancer risk in Ashkenazi Jewish ancestry. Preclinical models suggest MMS22L loss can confer sensitivity to PARP inhibitors, making prognosis and treatment impact important.\"},{\"question\":\"How were the patients and outcomes evaluated in this study?\",\"answer\":\"Seven MMS22L F722fs carriers with prostate cancer diagnosed at Johns Hopkins were followed longitudinally. Outcomes included survival status, disease-free status after treatment, biochemical recurrence and progression, and treatment responses reported in the series.\"},{\"question\":\"What treatment response and survival outcomes were observed, and was PARPi used?\",\"answer\":\"With follow-up ranging from 5 to 27 years, five of seven patients initially treated with radical prostatectomy remained alive and disease-free, including some who received adjuvant or salvage therapies. The remaining two metastatic-at-diagnosis patients showed prolonged response to ADT in one case, while the other died of unknown causes 5 years after diagnosis; none received PARPi.\"}]","Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation | PDF",1790125919,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0371d834784d967fbdcf5dea14f95721.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7126d079c90a4d7e3032ccde0ac7d9a.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/524027fc026e1a9e620729b40e7a7f62.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/532d5ad78a30e5539bde832dcc0cde06.webp",980,1287]